Massachusetts General Hospital in Boston established its immunotherapy toxicity service care team in part because of the experience of David M., a patient treated there for metastatic melanoma that spread to the lung and brain.

Kerry L. Reynolds, MD, director of the Severe Immunotherapy Complications Service, told her audience at the 18th International Kidney Cancer Symposium that David’s case forced physicians at Mass Gen to consider how to prepare doctors to handle immune-related adverse events (IRAEs) and create best practices for managing these incidents.

Read more from Targeted Oncology.